Myriad Genetics, Inc. (NASDAQ:MYGN)’s share price dropped NaN during trading on Thursday . The company traded as low as $27.23 and last traded at $0.00. Approximately 3,049,259 shares traded hands during trading, an increase of Infinity from the average daily volume of 0 shares.

MYGN has been the subject of a number of recent research reports. BidaskClub downgraded shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Monday, July 17th. Barclays PLC lowered their price target on shares of Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “hold” rating and set a $23.00 target price (up from $21.00) on shares of Myriad Genetics in a report on Thursday, August 10th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $22.00 target price on shares of Myriad Genetics in a report on Friday, July 14th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $26.40.

The stock has a market cap of $1.98 billion, a P/E ratio of 26.94, a PEG ratio of 1.84 and a beta of 0.24. The company has a quick ratio of 1.26, a current ratio of 1.46 and a debt-to-equity ratio of 0.13.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.04. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The company had revenue of $200.50 million for the quarter, compared to analyst estimates of $193.71 million. During the same period last year, the company earned $0.36 earnings per share. The business’s revenue was up 7.5% compared to the same quarter last year. analysts anticipate that Myriad Genetics, Inc. will post 1.04 earnings per share for the current fiscal year.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of Myriad Genetics stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $30.30, for a total transaction of $909,000.00. Following the sale, the director now directly owns 52,524 shares of the company’s stock, valued at $1,591,477.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Myriad Genetics by 168,335.7% in the 1st quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock worth $183,203,000 after purchasing an additional 9,536,219 shares during the period. Vanguard Group Inc. raised its holdings in Myriad Genetics by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock valued at $162,992,000 after acquiring an additional 56,708 shares during the period. Dimensional Fund Advisors LP raised its holdings in Myriad Genetics by 29.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,430,216 shares of the company’s stock valued at $88,636,000 after acquiring an additional 787,396 shares during the period. Thrivent Financial For Lutherans raised its holdings in Myriad Genetics by 7,026.7% in the 2nd quarter. Thrivent Financial For Lutherans now owns 2,742,340 shares of the company’s stock valued at $70,862,000 after acquiring an additional 2,703,860 shares during the period. Finally, Northern Trust Corp increased its holdings in shares of Myriad Genetics by 31.1% during the second quarter. Northern Trust Corp now owns 1,292,588 shares of the company’s stock worth $33,400,000 after purchasing an additional 306,276 shares during the period.

TRADEMARK VIOLATION NOTICE: “Myriad Genetics, Inc. (MYGN) Stock Price Down NaN” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/myriad-genetics-inc-mygn-stock-price-down-nan/1676751.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.